Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a
specialty pharmaceutical company that develops and
markets solutions for the treatment of dermatological
conditions and advanced tissue care, today announced the launch of
Ceramax™ Skin Barrier Cream, intended to be used as a topical skin
care preparation to relieve and to manage the burning and itching
associated with various dermatoses including atopic dermatitis,
irritant contact dermatitis, radiation dermatitis and other dry
skin conditions.
Ceramax is the result of a collaborative
initiative with the Lipogrid Company of Sweden, and
underscores Oculus’ ongoing growth strategy to license or acquire
differentiated, patent-protected technologies. This partnership was
announced in March 2016.
Ceramax, based on Lipogrid technology, allows the
physiological lipids to blend in with the skin’s natural lipid
building blocks and penetrate beyond the stratum corneum, where
they also contribute to the synthesis of ceramides, cholesterol,
and other free fatty acids. Testing has demonstrated that Ceramax
delivers phospholipid building blocks to the epidermis. Clinical
testing showed that patients exhibited consistent symptom
improvement while enabling the reduced use, and in some cases the
elimination, of steroids in the treatment protocol. The product
received FDA 510(k) clearance in November 2015.
“This is a most valuable addition to our product
portfolio and provides dermatologists with the latest advance in
skin barrier technology,” said Jeffrey Day, president of IntraDerm
Pharmaceuticals, Oculus’ dermatology division. “Ceramax is one of
the most advanced and safest skin barrier products in the
world. It hydrates and repairs the skin from the inside out
and protects from the outside in while simultaneously reducing the
need for steroids.”
Ceramax is marketed by IntraDerm Pharmaceuticals,
Oculus’ U.S. dermatology division with a full-time sales force of
16. More information is available at www.intraderm.com.
About Atopic DermatitisIn a 2009
Global Data study, it was estimated the global atopic dermatitis
therapeutics market delivered revenues of $643 million in 2009. It
is expected to grow to $810 million at a Compound Annual Growth
Rate (CAGR) of 3.4% by 2016. Globally, the United States remains
the largest market for atopic dermatitis therapeutics, and
generated revenue of $402 million in 2009. It is forecast to grow
at a CAGR of 3.8% over the next seven years to reach $582 million
by 2016.
Symptoms of atopic dermatitis are characterized by
itchy skin, which can lead to rash, redness, swelling, crusting and
scaling. The disease affects up to 20 percent of infants and young
children, who continue to have symptoms as adults with significant
impact on their quality of life. The exact cause is unknown, but
genetics are considered a key factor.
Topical corticosteroids (such as hydrocortisone,
betamethasone, and fluticasone) are the most common treatment for
atopic dermatitis. As eczema tends to be persistent, most
people will have to use topical steroids on and off for many years.
If used continuously topical steroids may lose their effectiveness
after a few weeks. This is known as tachyphylaxis.
Lipogrid® TechnologyLipogrid is a
lipid structural matrix of solid lipid particles and vesicles
comprised of fatty acids, cholesterol-type stabilizers,
phospholipids and ceramides with a carrier function, used in the
treatment of skin disorders.
About IntraDerm PharmaceuticalsA
division of Oculus Innovative Sciences, IntraDerm Pharmaceuticals
is a global dermatology enterprise with an initial focus on
dermatology products. The division’s headquarters are in
Petaluma, California with additional sales operations in the
Netherlands, and manufacturing operations in the United States and
Latin America. Products offered include non-steroidal options
for relief of pain and itch associated with dermal irritations, a
dermal spray for care of acute and chronic dermal lesions and a
scar management gel for minimizing scarring during and after
healing. More information can be found at
www.intraderm.com.
About Oculus Innovative Sciences,
Inc.Oculus Innovative Sciences is a specialty
pharmaceutical company that develops and markets solutions for
the treatment of dermatological conditions and advanced tissue
care. The company’s products, which are sold throughout the
United States and internationally, have improved outcomes for more
than five million patients globally by reducing infections,
itch, pain, scarring and harmful inflammatory responses. The
company's headquarters are in Petaluma, California,
with manufacturing operations in the United States and Latin
America. European marketing and sales are headquartered in
Roermond, Netherlands. More information can be found at
www.oculusis.com.
Forward-Looking StatementsExcept
for historical information herein, matters set forth in this
press release are forward-looking within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act
of 1995, including statements about the commercial and technology
progress and future financial performance of Oculus Innovative
Sciences, Inc. and its subsidiaries (the “Company”). These
forward-looking statements are identified by the use of words such
as “intended,” “provides,” and “marketed,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the Company’s business
that could cause actual results to vary,
including such risks that regulatory clinical and
guideline developments may change, scientific data may not be
sufficient to meet regulatory standards or receipt of required
regulatory clearances or approvals, clinical results may not
be replicated in actual patient settings, protection offered
by the Company’s patents and patent applications may be
challenged, invalidated or circumvented by its
competitors, the available market
for the Company’s products will not be as large as
expected, the Company’s common stock and warrants may be delisted
from NASDAQ, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies, the
Company may not meet its future capital needs, the Company may
not be able to obtain additional funding, as well as uncertainties
relative to varying product formulations and a multitude of diverse
regulatory and marketing requirements in different countries and
municipalities, and other risks detailed from time to time in the
Company’s filings with the Securities and Exchange Commission
including its annual report on Form 10-K for the year ended
March 30, 2015. The Company disclaims any obligation to update
these forward-looking statements, except as required by law.
Oculus®, Microcyn® Technology and IntraDerm
Pharmaceuticals™ are trademarks or registered trademarks of Oculus
Innovative Sciences, Inc. All other trademarks and service marks
are the property of their respective owners.
Media and Investor Contact:
Oculus Innovative Sciences, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@oculusis.com
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jul 2023 to Jul 2024